HemoCue® History
1974
Jan Lilja, laboratory engineer, and Sven-Erik Nilsson, computer expert, of the Kristianstad Hospital Clinical Laboratory begin outlining an improved method for measuring haemoglobin.
1977
The soundness of the method and the feasibility of cuvette production are proven.
1979
A license agreement with pharmaceutical company Leo is signed. Toward the end of the year, Lilja and Nilsson move into Leo's premises.
1982
Leo begins selling and distributing the first haemoglobin instruments.
1986
The haemoglobin system is successfully introduced on the US market. Turnover rises almost 80%.
1987
Leo is purchased by Pharmacia.
1988
Leo Diagnostics is bought out by the management and HemoCue® AB is formed.
1990
Acquisition of US Distributor - HemoCue®, Inc. is founded
1991
The glucose system, based on the same principles as the haemoglobin system, is introduced to the market.
1992
HemoCue® finds a new owner: Mallinckrodt Inc of Saint Louis, Missouri, USA.
1995
The first HemoCue® School takes place in Norrköping, Sweden.
1999
HemoCue® is acquired by EQT, a private equity group in northern Europe. Annual turnover exceeds $40 million.
A new system, HemoCue® Plasma/Low Hb system, is introduces. The system is used to determination of low haemoglobin levels in plasma, serum and aqueous solutions.
2000
HemoCue® Donor Hb Checker, a system for measuring haemoglobin in blood donors, is introduced.
2001
The 201+ system for glucose is introduced.
By introducing a Urine Albumin analyzer for detecting microalbuminuria, HemoCue® enters yet another significant testing area.
2002
The 201+ system for glucose is followed by a 201+ system for both glucose and haemoglobin making it possible to store test and QC results in the analyzer.
2003
HemoCue® makes extensive investments in production technology, R&D, sales and marketing.
Acquisition of Biotest. Distribution agreements with McKesson and PSS.
2004
HemoCue® Hb 201 and Gl 201 Data Management systems are launched in Europe.
2005
Market introduction of HemoCue® (Home Glucose).
2006
Market introduction of HemoCue® Albumin 201, HemoCue® Hb 301 and HemoCue® Glucose 201 RT.
2007
HemoCue® is acquired by Quest Diagnostics (www.questdiagnostics.com) a leading provider of diagnostic testing, information and services.
2008
Market introduction of HemoCue® WBC, a system for determination of total white blood cell count.
HemoCue® Albumin 201 system receives first FDA CLIA waiver in diagnostics industry for quantitative Point-of-Care test for Microalbuminuria.
2010
HemoCue® WBC DIFF is introduced. A system that provides a quantitative determination of white blood cells with a five part differential count of neutrophils, lymfocytes, monocytes, eosinphils and basophils.
More Information
Do you want more information or to get in contact with us?
Phone: 0844 88 00 996
Is any information missing?
Please let our webmaster know >>
Share
Did you like this page? Share with others.
